By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half,

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with specific gene mutations, outperforming AstraZeneca's Faslodex. The findings, presented at the American Society of Clinical Oncology meeting,

AstraZeneca India Pharma on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Osimertinib tablets in strength of 40mg and 80mg.